{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04422912",
            "orgStudyIdInfo": {
                "id": "CAB-101"
            },
            "organization": {
                "fullName": "Cabaletta Bio",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)",
            "officialTitle": "A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-phase-open-label-safety-and-dosing-study-of-autologous-cart-cells-desmoglein-chimeric-autoantibody-receptor-t-cells-caart-or-specific-chimeric-antigen-receptor-t-cells-caba-in-subjects-with-active-pemphigus-vulgaris-reset-pv"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-09-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2029-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-06-02",
            "studyFirstSubmitQcDate": "2020-06-05",
            "studyFirstPostDateStruct": {
                "date": "2020-06-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Cabaletta Bio",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \\[DSG3-CAART\\] or CD19-specific Chimeric Antigen Receptor T cells \\[CABA-201\\]) in subjects with active, pemphigus vulgaris",
            "detailedDescription": "Pemphigus vulgaris (PV) is a B-cell mediated autoimmune disorder in which painful blisters are formed on the skin or mucosal membrane, including the mouth, nose, throat, eyelids, anus, and genitals. This phase 1/2 study is being conducted to find the maximum tolerated dose and optimal fractionated infusion schedule of an investigational cell therapy, DSG3-CAART, that can be given to patients with mucosal PV who are inadequately managed by standard therapies. A sub-study will be conducted to investigate if CABA-201 can be safely administered while achieving clinical responses without the need for preconditioning in PV patients. DSG3-CAART or CABA-201 may potentially lead to complete and durable remission of disease."
        },
        "conditionsModule": {
            "conditions": [
                "Pemphigus Vulgaris"
            ],
            "keywords": [
                "Pemphigus",
                "Pemphigus Vulgaris",
                "CAAR-T Therapy",
                "CAR-T Therapy",
                "Desmoglein 3",
                "Cell Therapy",
                "Autoimmune Disease",
                "Autoimmunity",
                "Skin Diseases, Vesiculobullous",
                "Immunotherapy, Adoptive",
                "Immune System Diseases",
                "CABA-201",
                "Anti-CD19 CAR-T therapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 55,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "DSG3-CAART or CABA-201",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort A: Fractionated infusions of DSG3-CAART at increasing dose levels (6-9 groups) administered as a single cycle.\n\nCohort B: Consolidation of infusion of DSG3-CAART to fewer fractionations than in Cohort A using the selected dose from Cohort A (1 group) administered as a single cycle.\n\nCohort C: Infusion of final selected dose and fractionation of DSG3-CAART from Cohorts A and B (1 group) administered as a single cycle.\n\nOR\n\nCABA-201 Cohort: Single infusion of CABA-201.",
                    "interventionNames": [
                        "Biological: DSG3-CAART or CABA-201"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "DSG3-CAART or CABA-201",
                    "description": "Intravenous infusions of DSG3-CAART alone at different doses and different fractionations. Subjects may also receive varying doses of DSG3-CAART as part of a sub-study, which will employ pre-treatment with intravenous immunoglobulin, cyclophosphamide, and with or without fludarabine to potentially increase the in vivo expansion, persistence and activity of DSG3-CAART.\n\nOR\n\nCABA-201: Single intravenous infusion of CABA-201.",
                    "armGroupLabels": [
                        "DSG3-CAART or CABA-201"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse events, including Dose Limit Toxicity",
                    "description": "Incidence of adverse events that are related to DSG3-CAART therapy",
                    "timeFrame": "3 months"
                },
                {
                    "measure": "For CABA-201 Sub-study: To evaluate adverse events reported by subjects",
                    "description": "Incidence and severity of AEs",
                    "timeFrame": "Up to 28 days after CABA-201 infusion"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percent of CAAR-transduced cells",
                    "description": "Percent of total cells for infusion that are CAAR-transduced cells by flow cytometry",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Total DSG3-CAART positive cells",
                    "description": "Total DSG3-CAART positive cells for each manufacturing run by flow cytometry",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Cellular kinetics profile of DSG3-CAART",
                    "description": "Cellular kinetics profile of DSG3-CAART assessed by quantitative polymerase chain reaction",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "Change in DSG3 autoantibody titer",
                    "description": "Change in DSG3 autoantibody titer by ELISA compared to pre-infusion visit",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "Serologic remission",
                    "description": "Proportion of subjects achieving serologic remission, determined by negative DSG3 ELISA titer",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "Pemphigus Disease Area Index (PDAI)",
                    "description": "Change in PDAI compared to pre-infusion visit, scored on a 0-250 scale where a greater number represents more disease activity",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "Clinical remission: complete remission off therapy and complete remission on minimal therapy",
                    "description": "Proportion of subjects achieving complete remission, determined by a PDAI activity score of 0 for at least 2 months, either off therapy or on minimal therapy",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "Time to clinical remission and time to serologic remission",
                    "description": "Time to clinical remission and time to serologic remission from the last infusion",
                    "timeFrame": "up to 36 months"
                },
                {
                    "measure": "Duration of clinical remission and duration of serologic remission",
                    "description": "Duration of clinical remission and duration of serologic remission sustained after achieving the initial remission",
                    "timeFrame": "up to 36 months"
                },
                {
                    "measure": "For CABA-201 Sub-study: To evaluate adverse events reported by subjects",
                    "description": "Incidence and severity of AEs",
                    "timeFrame": "Up to 156 weeks after CABA-201 infusion"
                },
                {
                    "measure": "For CABA-201 Sub-study: To characterize the pharmacodynamics (PD)",
                    "description": "Levels of B cells in the blood",
                    "timeFrame": "Up to 156 weeks"
                },
                {
                    "measure": "For CABA-201 Sub-study: To characterize the pharmacokinetics (PK)",
                    "description": "Levels of CABA-201-positive T cells in the blood",
                    "timeFrame": "Up to 156 weeks"
                },
                {
                    "measure": "For CABA-201 Sub-study: To evaluate autoantibody -related biomarkers",
                    "description": "Levels of serum anti-DSG3 and anti-DSG1 antibodies",
                    "timeFrame": "Up to 156 Weeks"
                },
                {
                    "measure": "For CABA-201 Sub-study: To evaluate efficacy",
                    "description": "Absolute and percent change in disease activity by Pemphigus Disease Area Index (PDAI)",
                    "timeFrame": "Up to 156 Weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Confirmed diagnosis of mPV by prior or screening biopsy and prior positive anti- DSG3 antibody ELISA\n* mPV inadequately managed by at least one standard immunosuppressive therapies\n* Active mPV at screening\n* Anti-DSG3 antibody ELISA positive at screening\n\nInclusion Criteria for CABA-201 sub-study\n\n* Confirmed diagnosis of PV by prior or screening biopsy and prior positive DSG3 ELISA, IIF, and/or DIF\n* PV inadequately managed by at least one standard immunosuppressive therapy\n* Active PV at screening\n* DSG3 ELISA positive at screening\n\nExclusion Criteria:\n\n* Active cutaneous lesions associated with PV that indicates mucocutaneous rather than mucosal-dominant disease\n* Rituximab in last 12 months unless PV symptoms have recently worsened or anti-DSG3 antibody titers have recently increased\n* Prednisone \\> 0.25mg/kg/day\n* Other autoimmune disorder requiring immunosuppressive therapies\n* Investigational treatment in last 3 months\n\nExclusion Criteria for CABA-201 sub-study\n\n* Have paraneoplastic pemphigus or active malignancy (not including non-melanoma skin cancer)\n* Have received rituximab or other anti-CD20 or anti-CD19 therapies in last 12 months unless anti-DSG3 antibody titers have recently increased or PV symptoms have recently worsened\n* Prednisone \\> 0.25mg/kg/day\n* Other autoimmune disorder requiring immunosuppressive therapies\n* Investigational treatment in last 3 months",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Cabaletta Bio",
                    "role": "CONTACT",
                    "phone": "+1 267 759 3100",
                    "phoneExt": "4444",
                    "email": "clinicaltrials@cabalettabio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Cabaletta Bio",
                    "affiliation": "Cabaletta Bio",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford University, Dept. of Dermatology",
                    "status": "RECRUITING",
                    "city": "Redwood City",
                    "state": "California",
                    "zip": "94063",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Isin Sinem Bagci, MD",
                            "role": "CONTACT",
                            "phone": "650-724-8829",
                            "email": "isbagci@stanford.edu"
                        },
                        {
                            "name": "Kunju Sridhar, PhD",
                            "role": "CONTACT",
                            "phone": "650 721 4902",
                            "email": "kunju@stanford.edu"
                        },
                        {
                            "name": "M. Peter Marinkovich, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.48522,
                        "lon": -122.23635
                    }
                },
                {
                    "facility": "UC Davis, Dept. of Dermatology",
                    "status": "RECRUITING",
                    "city": "Sacramento",
                    "state": "California",
                    "zip": "95816",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lauren Downing",
                            "role": "CONTACT",
                            "phone": "916-551-2635",
                            "email": "ladowning@ucdavis.edu"
                        },
                        {
                            "name": "Mehrdad Abedi, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.58157,
                        "lon": -121.4944
                    }
                },
                {
                    "facility": "Northwestern University",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "NU Dermatology CTU",
                            "role": "CONTACT",
                            "phone": "312-503-5944",
                            "email": "NUderm-research@northwestern.edu"
                        },
                        {
                            "name": "Alan Zhou, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "University of Iowa",
                    "status": "RECRUITING",
                    "city": "Iowa City",
                    "state": "Iowa",
                    "zip": "52242",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amanda Steahr",
                            "role": "CONTACT",
                            "phone": "319-384-6843",
                            "email": "amanda-steahr@uiowa.edu"
                        },
                        {
                            "name": "Janet Fairley, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.66113,
                        "lon": -91.53017
                    }
                },
                {
                    "facility": "Mount Sinai - Icahn School of Medicine",
                    "status": "WITHDRAWN",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University of North Carolina, Department of Dermatology",
                    "status": "WITHDRAWN",
                    "city": "Chapel Hill",
                    "state": "North Carolina",
                    "zip": "27516",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.9132,
                        "lon": -79.05584
                    }
                },
                {
                    "facility": "University of Pennsylvania",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jami Sybesma",
                            "role": "CONTACT",
                            "email": "Jami.Sybesma@Pennmedicine.upenn.edu"
                        },
                        {
                            "name": "David Porter, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "UT Southwestern Medical Center, Dept. of Dermatology",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75235",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Aleuna Lee",
                            "role": "CONTACT",
                            "phone": "214-645-8968",
                            "email": "aleuna.lee@utsouthwestern.edu"
                        },
                        {
                            "name": "Arturo Dominguez, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "MD Anderson Texas Medical Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Dermatology Department",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Omar Pacha, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "University of Washington",
                    "status": "WITHDRAWN",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010392",
                    "term": "Pemphigus"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012872",
                    "term": "Skin Diseases, Vesiculobullous"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13303",
                    "name": "Pemphigus",
                    "asFound": "Pemphigus Vulgaris",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15675",
                    "name": "Skin Diseases, Vesiculobullous",
                    "relevance": "LOW"
                },
                {
                    "id": "T4478",
                    "name": "Pemphigus",
                    "asFound": "Pemphigus",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4481",
                    "name": "Pemphigus Vulgaris",
                    "asFound": "Pemphigus Vulgaris",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "relevance": "LOW"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4625",
                    "name": "Autoantibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "relevance": "LOW"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M19117",
                    "name": "Immunoglobulins, Intravenous",
                    "relevance": "LOW"
                },
                {
                    "id": "M8836",
                    "name": "gamma-Globulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M20191",
                    "name": "Rho(D) Immune Globulin",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}